Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration

Ocugen (OCGN) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.

MT NewswiresApr 19 20:19

Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a

OcugenApr 19 12:00

Ocugen Stock Jumps After $175M Securities Filing

Seeking AlphaApr 18 18:21

Ocugen (OCGN.US): The 2023 Q4 financial report achieved revenue of US$6.036 million, previous value of US$0; earnings per share were -0.04 USD, previous value was -0.10 USD, and expected value was -0.06 USD.

Ocugen (OCGN.US): The 2023 Q4 financial report achieved revenue of US$6.036 million, previous value of US$0; earnings per share were -0.04 USD, previous value was -0.10 USD, and expected value was -0.06 USD.

Zhitong FinanceApr 17 06:50

Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...

Stockhouse Apr 14 23:00

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a

OcugenApr 12 12:00